$401 Million is the total value of 5AM Venture Management, LLC's 24 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS INC | $118,346,875 | -6.8% | 5,798,475 | 0.0% | 29.48% | -9.2% | ||
| ENTRADA THERAPEUTICS INC | $66,742,858 | +4.4% | 4,408,379 | 0.0% | 16.63% | +1.7% | ||
| Sell | DISC MEDICINE INC | $21,686,825 | +73.9% | 488,442 | -17.0% | 5.40% | +69.4% | |
| RALLYBIO CORP | $20,549,898 | -0.9% | 3,630,724 | 0.0% | 5.12% | -3.5% | ||
| VOR | VOR BIOPHARMA INC | $19,657,724 | -42.6% | 6,361,723 | 0.0% | 4.90% | -44.1% | |
| Buy | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $18,231,786 | +2093.6% | 357,486 | +820.0% | 4.54% | +2032.4% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $15,538,394 | +12.2% | 862,286 | 0.0% | 3.87% | +9.3% | |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $13,822,900 | – | 490,000 | +100.0% | 3.44% | – |
| SCPH | SCPHARMACEUTICALS INC | $12,234,593 | +12.3% | 1,200,647 | 0.0% | 3.05% | +9.4% | |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $10,527,461 | – | 310,270 | +100.0% | 2.62% | – |
| VKTX | Buy | VIKING THERAPEUTICS INC | $9,482,850 | +62.7% | 585,000 | +67.1% | 2.36% | +58.5% |
| COGT | COGENT BIOSCIENCES INC | $9,358,810 | +9.7% | 790,440 | 0.0% | 2.33% | +6.9% | |
| PHVS | PHARVARIS N V | $8,896,264 | +88.0% | 587,600 | 0.0% | 2.22% | +83.1% | |
| ARVN | ARVINAS INC | $7,942,400 | -9.2% | 320,000 | 0.0% | 1.98% | -11.5% | |
| RNA | AVIDITY BIOSCIENCES INC | $7,381,005 | -27.8% | 665,555 | 0.0% | 1.84% | -29.6% | |
| ANAB | ANAPTYSBIO INC | $7,276,289 | -6.5% | 357,733 | 0.0% | 1.81% | -8.9% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $6,955,025 | – | 192,500 | +100.0% | 1.73% | – |
| VRDN | VIRIDIAN THERAPEUTICS INC | $6,661,200 | -6.5% | 280,000 | 0.0% | 1.66% | -8.9% | |
| SPRB | SPRUCE BIOSCIENCES INC | $5,082,600 | -2.7% | 2,364,000 | 0.0% | 1.27% | -5.2% | |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $4,293,450 | -11.8% | 1,305,000 | +10.1% | 1.07% | -14.1% |
| FIXX | HOMOLOGY MEDICINES INC | $4,014,288 | -14.1% | 4,535,919 | 0.0% | 1.00% | -16.3% | |
| IMPL | IMPEL PHARMACEUTICALS INC | $3,663,685 | -9.3% | 2,884,791 | 0.0% | 0.91% | -11.6% | |
| GHRS | New | GH RESEARCH PLCordinary shares | $1,803,741 | – | 152,022 | +100.0% | 0.45% | – |
| CDTX | CIDARA THERAPEUTICS INC | $1,281,997 | -11.0% | 1,134,511 | 0.0% | 0.32% | -13.3% | |
| Exit | PEAR THERAPEUTICS INC | $0 | – | -16,744,113 | -100.0% | -1.09% | – | |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -284,626 | -100.0% | -1.77% | – |
| FGEN | Exit | FIBROGEN INC | $0 | – | -579,434 | -100.0% | -2.76% | – |
| IDYA | Exit | IDEAYA BIOSCIENCES INC | $0 | – | -868,520 | -100.0% | -3.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HOMOLOGY MEDICINES INC | 16 | Q3 2023 | 26.6% |
| ARVINAS INC | 16 | Q3 2023 | 14.3% |
| Crinetics Pharmaceuticals, Inc. | 16 | Q3 2023 | 12.8% |
| SCPHARMACEUTICALS INC | 16 | Q3 2023 | 7.5% |
| CIDARA THERAPEUTICS INC | 16 | Q3 2023 | 1.7% |
| IDEAYA BIOSCIENCES INC | 14 | Q1 2023 | 11.4% |
| VOR BIOPHARMA INC | 11 | Q3 2023 | 51.9% |
| CABALETTA BIO INC | 11 | Q2 2022 | 14.2% |
| AKOUOS INC | 10 | Q3 2022 | 27.7% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.1% |
View 5AM Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-03 |
| 13F-HR | 2021-11-15 |
View 5AM Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.